Serial No. 09/806,400 Applicant(s): Schoenfeld et al.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1-13 (Canceled)

Claim 14 (Currently Amended) A method for prevention or treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of an enteric coated composition comprising one or more active components selected from the group consisting of isolated copper-oxidized low density lipoprotein (Ox LDL) and malondialdehyde LDL (MDA-LDL) and a pharmaceutically acceptable carrier for oral administration, wherein said administration is in a sufficient amount to induce production of IL-10 or TGFβ and to suppress IFN γ, thereby inhibiting at least one atherosclerosis related symptom in said subject.

Claim 15-27 (Canceled)

Claim 28 (Currently Amended) A method for prevention or treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of an enteric coated composition comprising one or more active components selected from the group consisting of human modified low density lipoprotein and isolated human copper-oxidized low density lipoprotein and a pharmaceutically acceptable carrier for oral administration, wherein said administration is in a sufficient amount to induce production of IL-10 or TGFβ and to suppress IFN γ, thereby inhibiting at least one atherosclerosis-related symptom in said subject.